Dipeptidyl peptidase-4 inhibitors in progressive kidney disease

scientific article

Dipeptidyl peptidase-4 inhibitors in progressive kidney disease is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1097/MNH.0000000000000080
P698PubMed publication ID25415611

P2093author name stringYuichi Makino
Masakazu Haneda
Yukihiro Fujita
P433issue1
P304page(s)67-73
P577publication date2015-01-01
P1433published inCurrent Opinion in Nephrology and HypertensionQ15756282
P1476titleDipeptidyl peptidase-4 inhibitors in progressive kidney disease
P478volume24

Reverse relations

cites work (P2860)
Q97523452Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study
Q42050075Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure.
Q26739999Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Q47215463Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Q38527885The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?
Q88393664The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors

Search more.